PRESS RELEASE
19 November 2026 08:52:00 CET

Alzinova plans a blinded twelve-month interim analysis and a separate futility analysis in ADVANCE

Alzinova AB (“Alzinova” or the “Company”) today announces the planned interim analyses in the Company's Phase 2a study ADVANCE (ALZ-C-002) of its therapeutic vaccine ALZ-101 in early Alzheimer's disease. The plan comprises a twelve-month blinded interim analysis and a separate non-binding futility analysis. The planned analyses have been discussed with the Company's expert panel, including Professor Marwan Sabbagh, Global Principal Investigator for the ADVANCE study.

Twelve-month blinded interim analysis
When half of participants have completed the Week 52 assessment, a blinded interim analysis is planned. It will assess biomarkers and clinical measures at Week 52, including plasma phosphorylated tau-217 (p-tau217) and the Alzheimer's Disease Composite Score (ADCOMS). As the analysis will be performed on pooled data, without revealing treatment assignment, it is intended to provide an early indication of biomarker activity and clinical effect alongside safety and tolerability while maintaining the integrity of the ongoing study. Subject to enrolment, and study progression, this analysis is currently expected to be reportable around the third quarter of 2028.

Non-binding futility analysis
A non-binding futility analysis is planned for the third quarter of 2028, at the same timepoint as the twelve-month interim analysis, once approximately 50% of participants have completed the Week 52 assessment of the primary endpoint. It will be performed by independent, unblinded statisticians.

The futility analysis is designed to assess whether the available interim data support continuation of the study towards its final analysis. It is a safeguard and designed to recommend stopping the study only if the interim data make it unlikely that the primary endpoint will be met at the final analysis. As the analysis is non-binding, any recommendation will form part of the overall assessment of the study and will not in itself require the Company to stop the trial. As previously communicated, results from ADVANCE are anticipated in late 2029.

Professor Marwan Sabbagh, Global Principal Investigator for the ADVANCE study, comments:
“I have spent a good part of my career watching Alzheimer’s programmes wait years for a single cognitive readout and then discover that the biology was already telling us something. That is no longer an acceptable way to run a Phase 2a study. A blinded interim look at biomarkers and clinical effect, including p-tau217 and ADCOMS, while an independent group tests whether the study is futile, is the right use of an interim. It will tell us, much earlier than 2029, whether this programme deserves the time, the participants and the capital required to finish the study.”

About the ADVANCE study
ADVANCE is a randomised, double-blind, placebo-controlled Phase 2a study evaluating the clinical activity, safety, tolerability, immunogenicity and biomarker effects of ALZ-101 in approximately 120 participants aged 50–85 years with early Alzheimer's disease, defined as mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease according to NIA-AA criteria. The primary endpoint is the effect of ALZ-101 versus placebo on clinical progression, measured as change from baseline in the Alzheimer's Disease Composite Score (ADCOMS) through Week 52. The study is being conducted in the United States, the European Union and the United Kingdom. Results are anticipated in late 2029.

About ALZ-101
ALZ-101 is Alzinova's lead candidate, a therapeutic vaccine against Alzheimer's disease. Alzinova's patented AβCC peptide technology makes it possible to develop disease-modifying treatments that target the toxic amyloid-beta oligomers believed to be central to the onset and development of the disease with great accuracy. ALZ-101 has received Fast Track designation from the US FDA.

For further information, please contact:
Tord Labuda, CEO
E-mail: IR@alzinova.com

About Alzinova
Alzinova AB is a Swedish biopharmaceutical company in clinical development specializing in the treatment of Alzheimer's disease, with a focus on targeting toxic amyloid-beta oligomers. The lead candidate ALZ-101 is a therapeutic vaccine against Alzheimer's disease. Alzinova's patented AβCC peptide technology makes it possible to develop disease-modifying treatments that target the toxic amyloid-beta oligomers that are central to the onset and development of the disease with great accuracy. From a global perspective, Alzheimer's disease is one of the most common and devastating neurological diseases, with around 40 million people affected today. Based on the same technology, the company is also developing the antibody ALZ-201, which is currently in preclinical development, as well as the diagnostic project ALZ-401, which aims to develop a blood test to identify an increased risk of Alzheimer's disease before symptoms appear. The goal is to further expand the pipeline. The company's Certified Adviser on Nasdaq First North Growth Market is Mangold Fondkommission AB. For more information about Alzinova, please visit: **www.alzinova.com**

This information is information that Alzinova is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-11-19 08:52 CET.

Attachments

Alzinova plans a blinded twelve-month interim analysis and a separate futility analysis in ADVANCE